Bezlotoxumab

Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention^[1][2][3]. IC50 & Target:toxin B In Vitro: Bezlotoxumab (100 μg/mL, 18 h pre-treatment) neutralizes TcdB-induced TER reduction in Caco-2 and MOCK cell monolayers^[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) shows increased transport to the apical chamber of Caco-2 cells with rising TcdB concentration^[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) inhibits TcdB-induced TER decrease in T84 cell monolayers, with Fc-independent neutralizing effects^[1].
In Vivo: Bezlotoxumab (250 μg/mouse, i.p., 1 day pre-infection) improves survival of both WT and FcRn^-/- C57BL/6 mice in primary CDI model, combined with Actoxumab (HY-P99277)^[1].
Bezlotoxumab (50 mg/kg, s.c., q.d. for 4 days) enhances survival and reduces symptoms in 100 g male Syrian hamsters with CDI combined with Actoxumab^[1].